Retractable Technologies Inc (RVP) Stock Analysis and Metrics

Retractable Technologies

NYSE: RVP

$0.68 ▲ +0.00 (+0.01%)

At close: Jul 24, 2026 · 1:38 PM UTC

Financial Ratios

Market Cap20.36 Mn

P/E-3.12

P/S0.55

Div. Yield0.00

ROIC (Qtr)-0.16

Total Debt (Qtr)806,433.00

Revenue Growth (1y) (Qtr)-13.48

Add ratio to table…

About

Retractable Technologies, Inc. manufactures and markets safety medical products, predominantly syringes and needles, for the healthcare industry. The company’s core offerings include the VanishPoint® line of retractable syringes, the Patient Safe® series, and the EasyPoint® retractable needle platform. These products incorporate safety mechanisms designed to protect healthcare workers from needlestick injuries and to reduce cross contamination. Retractable Technologies, Inc. operates manufacturing facilities in Little Elm, Texas and utilizes contract manufacturers in China to support production. The firm also invests in expanding domestic capacity through government agreements to lessen reliance on imported components.

Revenue is generated from the sale of injection devices sold under the VanishPoint®, Patient Safe®, and EasyPoint® brands. In recent years, VanishPoint® 1mL syringes have represented the largest share of sales, accounting for 65.1% of revenue in 2025, 68.5% in 2024 and 78.3% in 2023. EasyPoint® products contributed 31.2% of sales in 2025, 27.1% in 2024 and 16.6% in 2023. The company distributes its products through general line and specialty distributors within the United States and through international distributors abroad. Purchasing decisions are frequently made by group purchasing organizations and institutional buying groups that supply hospitals, clinics and alternate care sites.

Retractable Technologies, Inc. competes in the safety syringe and needle market against larger established firms such as Becton, Dickinson and Company and its spun off entity Embecta Corp. The company’s competitive advantages stem from its proprietary retractable technology that allows needle retraction while the needle remains in the patient. VanishPoint® 1mL syringes meet low dead space criteria set by pharmaceutical manufacturers, which reduces medication waste and can permit additional doses from a vial. EasyPoint® needles provide automated retraction that can be activated with fluid in the syringe, enabling use in blood collection and aspiration procedures. Retractable Technologies, Inc. emphasizes lower lifecycle costs by factoring in reduced needlestick injury treatment and disposal expenses, allowing its price to be competitive or lower than rivals.

The company sells its products to healthcare providers including hospitals, outpatient clinics, alternate care sites and long term care facilities. A significant portion of sales is domestic, with the majority of purchases made through group purchasing organizations that negotiate contracts on behalf of their members. These organizations often enter into agreements with large distributors, which can limit market entry for smaller competitors. Retractable Technologies, Inc. also supplies the United States government through agreements such as the Technology Investment Agreement with the Department of Defense and BARDA, supporting domestic manufacturing capacity. Internationally, the company relies on distributors to reach customers in foreign markets, though international sales represent a smaller share of total revenue.

Investment Thesis

▲ Bull case

The company’s strategic shift toward domestic manufacturing is already yielding tangible cost benefits that the market has not fully priced in. In the Q1 FY26 domestic production accounted for 39% of total output up from lower levels in prior periods directly reducing exposure to the steep tariff rates on Chinese imports. This shift lowers freight and duty expenses which contributed to a 3.1% decline in cost of manufactured product year over year. As the firm continues to expand its domestic capabilities the gross margin profile is poised to improve meaningfully over the next several quarters.
The recent workforce reduction of approximately 16% is expected to generate annual savings of $2.2 million in wages and benefits representing roughly 13% of total workforce costs. These savings will flow directly into operating income offsetting the one‑time separation payments of about $122 thousand. By trimming headcount the company is also streamlining its organizational structure which should enhance decision making speed and reduce overhead complexity. The cost savings combined with ongoing tariff mitigation create a clearer path to breakeven operating performance in the near term.
The declaration of dividends on Series II and Series III Class B Convertible Preferred Stock at $1.00 per share per annum signals that the board believes the company has sufficient cash flow to return capital to shareholders. This action reflects confidence in the sustainability of earnings despite the reported operating loss and suggests that internal cash generation is stronger than the headline numbers indicate. Preferred dividends also provide a non‑dilutive source of return that can attract income‑focused investors and potentially support a higher valuation multiple. The market may be underestimating the positive signalling effect of these distributions on investor sentiment.
Growth in EasyPoint needle sales both domestically and internationally represents a structural catalyst that is not yet fully reflected in the stock price. International revenues rose 42.4% year over year driven primarily by higher EasyPoint needle shipments indicating successful penetration of foreign markets despite lower average selling prices. The EasyPoint product addresses critical safety needs such as needlestick prevention and blood collection versatility which are increasingly mandated by healthcare regulators worldwide. Continued adoption of this platform could drive higher unit volumes and eventually improve product mix leading to better average selling prices and stronger gross margins.

The company’s strategic shift toward domestic manufacturing is already yielding tangible cost benefits that the market has not fully priced in. In the Q1 FY26 domestic production accounted for 39% of total output up from lower levels in prior periods directly reducing exposure to the steep tariff rates on Chinese imports. This shift lowers freight and duty expenses which contributed to a 3.1% decline in cost of manufactured product year over year. As the firm continues to expand its domestic capabilities the gross margin profile is poised to improve meaningfully over the next several quarters.
The recent workforce reduction of approximately 16% is expected to generate annual savings of $2.2 million in wages and benefits representing roughly 13% of total workforce costs. These savings will flow directly into operating income offsetting the one‑time separation payments of about $122 thousand. By trimming headcount the company is also streamlining its organizational structure which should enhance decision making speed and reduce overhead complexity. The cost savings combined with ongoing tariff mitigation create a clearer path to breakeven operating performance in the near term.
The declaration of dividends on Series II and Series III Class B Convertible Preferred Stock at $1.00 per share per annum signals that the board believes the company has sufficient cash flow to return capital to shareholders. This action reflects confidence in the sustainability of earnings despite the reported operating loss and suggests that internal cash generation is stronger than the headline numbers indicate. Preferred dividends also provide a non‑dilutive source of return that can attract income‑focused investors and potentially support a higher valuation multiple. The market may be underestimating the positive signalling effect of these distributions on investor sentiment.
Growth in EasyPoint needle sales both domestically and internationally represents a structural catalyst that is not yet fully reflected in the stock price. International revenues rose 42.4% year over year driven primarily by higher EasyPoint needle shipments indicating successful penetration of foreign markets despite lower average selling prices. The EasyPoint product addresses critical safety needs such as needlestick prevention and blood collection versatility which are increasingly mandated by healthcare regulators worldwide. Continued adoption of this platform could drive higher unit volumes and eventually improve product mix leading to better average selling prices and stronger gross margins.

▼ Bear case

Despite mitigation efforts the company remains exposed to significant tariff risk because a portion of its product lineup still relies on Chinese contract manufacturers. The prevailing tariff rate on most syringe and needle imports from China was 120% as of March 2026 and any policy shift could quickly erode the cost savings achieved through domestic production. The firm’s disclosure that it is still reliant on Chinese imports for products it cannot produce with current equipment highlights a structural vulnerability that could resurface if trade tensions intensify. This ongoing exposure creates uncertainty around future cost of goods sold and gross margin stability.
Operating losses persist and the underlying cost base remains elevated limiting the company’s ability to achieve sustainable profitability. In the Q1 FY26 the operating loss widened to $6.2 million from $4.7 million a year earlier driven by negative gross margin and higher donation expense. Operating expenses increased 14% or $655 thousand with a substantial portion attributable to non recurring consulting charges and charitable product donations. These elevated expenses suggest that the company’s cost discipline is still a work in progress and that any improvement in revenue may be offset by continued spending pressures.
Liquidity constraints are a material concern given the current cash position and debt load. At the end of 2025 cash stood at $2.6 million while the company held $34.4 million in debt and equity securities creating a leveraged balance sheet that could limit financial flexibility. The net decrease in cash for 2025 was $1.6 million indicating that cash consumption remains a challenge. Should operating performance not improve quickly the company may need to rely on external financing or asset sales to meet obligations which could dilute shareholders or increase financing costs.
Competitive pressures from larger medical device manufacturers pose a persistent threat to Retractable’s market share and pricing power. The safety product segment is characterized by consolidation where big players can leverage scale to offer lower prices and broader distribution networks. Retractable’s reliance on specialty and general line distributors makes it susceptible to channel shifts that favor larger suppliers. Moreover the firm’s acknowledgment of uncertainty regarding the timing of future international orders suggests that demand volatility could impede revenue growth. These factors together create a headwind that could constrain top line expansion and compress margins over the medium term.

Despite mitigation efforts the company remains exposed to significant tariff risk because a portion of its product lineup still relies on Chinese contract manufacturers. The prevailing tariff rate on most syringe and needle imports from China was 120% as of March 2026 and any policy shift could quickly erode the cost savings achieved through domestic production. The firm’s disclosure that it is still reliant on Chinese imports for products it cannot produce with current equipment highlights a structural vulnerability that could resurface if trade tensions intensify. This ongoing exposure creates uncertainty around future cost of goods sold and gross margin stability.
Operating losses persist and the underlying cost base remains elevated limiting the company’s ability to achieve sustainable profitability. In the Q1 FY26 the operating loss widened to $6.2 million from $4.7 million a year earlier driven by negative gross margin and higher donation expense. Operating expenses increased 14% or $655 thousand with a substantial portion attributable to non recurring consulting charges and charitable product donations. These elevated expenses suggest that the company’s cost discipline is still a work in progress and that any improvement in revenue may be offset by continued spending pressures.
Liquidity constraints are a material concern given the current cash position and debt load. At the end of 2025 cash stood at $2.6 million while the company held $34.4 million in debt and equity securities creating a leveraged balance sheet that could limit financial flexibility. The net decrease in cash for 2025 was $1.6 million indicating that cash consumption remains a challenge. Should operating performance not improve quickly the company may need to rely on external financing or asset sales to meet obligations which could dilute shareholders or increase financing costs.
Competitive pressures from larger medical device manufacturers pose a persistent threat to Retractable’s market share and pricing power. The safety product segment is characterized by consolidation where big players can leverage scale to offer lower prices and broader distribution networks. Retractable’s reliance on specialty and general line distributors makes it susceptible to channel shifts that favor larger suppliers. Moreover the firm’s acknowledgment of uncertainty regarding the timing of future international orders suggests that demand volatility could impede revenue growth. These factors together create a headwind that could constrain top line expansion and compress margins over the medium term.

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ALC	Alcon Inc	33,163,703.85 Bn	498,335.12	3.14 Mn	4.16 Bn
2	ISRG	Intuitive Surgical Inc	119.67 Bn	37.90	0.00 Mn	-
3	BDX	Becton Dickinson & Co	43.92 Bn	37.38	0.00 Mn	17.28 Bn
4	MDLN	Medline Inc.	31.71 Bn	56.52	0.00 Mn	12.57 Bn
5	RMD	Resmed Inc	28.46 Bn	18.73	0.00 Mn	0.66 Bn
6	WST	West Pharmaceutical Services Inc	23.80 Bn	45.05	0.00 Mn	0.20 Bn
7	COO	Cooper Companies, Inc.	13.77 Bn	58.38	0.00 Mn	2.46 Bn
8	SOLV	Solventum Corp	13.63 Bn	9.51	0.00 Mn	5.08 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password